Manifold, an AI platform built for life sciences, announced an $18 million Series B funding round led by Reach Capital, with participation from SilverArc Capital, Industry Ventures, and existing investors TQ Ventures and Calibrate Ventures. The raise brings total funding to $40 million and strengthens Manifold’s position as an emerging category leader in vertical AI for life sciences, supporting biopharma companies and medical centers across workflows from target identification to clinical development, market access, and precision medicine.
Vertical AI platforms are reshaping productivity across major industries by embedding domain-specific data, workflows, and governance. In life sciences, a $2 trillion sector where productivity directly affects patient outcomes, Manifold defines this category through purpose-built infrastructure for multimodal biomedical data, multi-entity collaboration, and workflows spanning bench to clinic.
“In every industry, companies that combine agentic AI and domain-specific context will transform productivity. Customers are seeking proven partners in this transformation. We believe Manifold is the emerging category leader for vertical AI in life sciences,” said Jennifer Carolan, Partner at Reach Capital.
The new funding supports expansion of the Agent OS to improve how AI agents operate on multimodal biomedical data, scientific tools, and institutional context, while also deepening collaboration infrastructure and scaling the data ecosystem to enable dataset creation with strong governance and data ownership.
Recent momentum includes expanded AI-driven workflows across research and clinical use cases, growing enterprise adoption by organizations such as Foundation Medicine and the University of Virginia, strategic collaborations with the Broad Institute, AWS, and Anthropic, and operation of Terra, serving thousands of researchers worldwide.
"Our customers and partners are pushing the boundaries of what's possible in life sciences, and we're honored to build alongside them. This funding accelerates our shared goal to transform productivity in life sciences and get life-changing medicines to patients faster,” said Vinay Seth Mohta, CEO, Manifold.